[Recommendations of the European League Against Rheumatism (EULAR) for the treatment of "large-vessel vasculitides"].
Wipfler-Freissmuth
E
E
Rheumaklinik Bad Bramstedt, Universitätsklinik Schleswig-Holstein, Bad Bramstedt, Deutschland. edith.wipfler@gmx.net
Moosig
F
F
Schirmer
M
M
D018501:Antirheumatic Agents / Q000009:adverse effects / Q000627:therapeutic use*; D001241:Aspirin / Q000009:adverse effects / Q000627:therapeutic use; D000068800:Etanercept; D005060:Europe; D019317:Evidence-Based Medicine; D013700:Giant Cell Arteritis / Q000175:diagnosis / Q000188:drug therapy*; D005938:Glucocorticoids / Q000009:adverse effects / Q000627:therapeutic use; D006801:Humans; D007074:Immunoglobulin G / Q000009:adverse effects / Q000627:therapeutic use; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D016032:Randomized Controlled Trials as Topic; D018124:Receptors, Tumor Necrosis Factor / Q000627:therapeutic use; D013625:Takayasu Arteritis / Q000175:diagnosis / Q000188:drug therapy*
D018501:Antirheumatic Agents; D005938:Glucocorticoids; D007074:Immunoglobulin G; D007166:Immunosuppressive Agents; D018124:Receptors, Tumor Necrosis Factor; D000068800:Etanercept; D001241:Aspirin